Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.80M | $5.17M | $7.39M | $7.56M | $7.58M | $20.5M | $27.7M | $20.4M | $27.0M | $22.4M |
| Revenue growth | — | 84.4% | 43.0% | 2.2% | 0.2% | 170.8% | 34.8% | -26.4% | 32.9% | -17.3% |
| Gross profit | -$830K | $1.31M | $1.76M | $2.60M | $2.51M | $3.96M | $9.65M | $5.98M | $13.3M | $12.7M |
| Gross margin | -29.6% | 25.4% | 23.9% | 34.4% | 33.2% | 19.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Operating income | -$11.1M | -$14.4M | -$17.7M | -$17.7M | -$29.9M | -$76.5M | -$56.8M | -$56.2M | -$57.7M | -$36.7M |
| Operating margin | -396.0% | -278.9% | -239.2% | -234.2% | -394.7% | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Net income | -$10.9M | -$15.7M | -$17.8M | -$17.7M | -$29.4M | -$76.8M | -$62.2M | -$59.4M | -$42.7M | -$41.7M |
| Net margin | -388.4% | -304.5% | -240.8% | -234.6% | -388.7% | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (diluted) | $2.09 | $1.64 | $15.63 | $8.00 | $4.01 | $4.07 | $2.54 | $1.93 | $12.27 | $10.12 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.38M | -$10.6M | -$11.5M | -$15.7M | -$17.7M | -$50.4M | -$47.8M | -$30.4M | -$38.6M | -$25.9M |
| Capital expenditures | $808K | $195K | $71.0K | $98.0K | $118K | $261K | $442K | $584K | $138K | $142K |
| Free cash flow | -$9.19M | -$10.8M | -$11.5M | -$15.8M | -$17.9M | -$50.7M | -$48.3M | -$31.0M | -$38.7M | -$26.1M |
| Share buybacks | — | — | — | — | — | — | $134K | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.09M | $3.72M | $11.0M | $20.4M | $28.6M | $35.8M | $49.4M | $36.8M | $27.8M | $21.8M |
| Total assets | $3.87M | $6.96M | $14.1M | $24.6M | $35.4M | $101M | $119M | $96.4M | $119M | $110M |
| Long-term debt | — | — | — | — | — | $0.00 | $18.1M | $24.6M | $23.5M | $30.7M |
| Shareholders' equity | -$6.54M | $3.94M | $8.93M | $18.9M | $28.2M | $85.5M | $80.0M | $58.1M | $72.0M | $67.9M |
| Retained earnings | -$55.0M | -$71.0M | -$89.3M | -$110M | -$143M | -$222M | -$286M | -$349M | -$390M | -$452M |
| Shares (wtd avg diluted) | 5.71M | 14.1M | 1.83M | 2.24M | 5.96M | 16.6M | 23.6M | 28.4M | 2.45M | 3.98M |
Every figure is extracted from DarioHealth Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.